The Science of Addiction in 2026: What We Actually Know
Addiction is a brain disease, genetics matter, and the science is moving faster than most clinicians can keep up with.
Body: [Draft covers: brain-disease model (mesolimbic dopamine, prefrontal control), genetic contribution (~50%), adolescent vulnerability, stress-relapse cycle, evidence for MAT, psychedelics renaissance (MDMA, psilocybin, ibogaine research), neuromodulation (TMS), digital therapeutics, and the NIH HEAL Initiative’s ~$500M/year investment. Clear disclaimer: brain-disease model doesn’t erase personal agency — it explains why willpower alone is insufficient.]
Related: Psychedelics research in 2026 | TMS for addiction — what the evidence says | “Addiction is a brain disease” — what that actually means.
Sources Cited
- 01.A
- 02.Ahttps://heal.nih.govNIH HEAL Initiative
Filed Under
Peer-Reviewed ResearchMAT — BuprenorphineFederal
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Xylazine Wound Care Has Been Guessing — Two Baltimore Studies Just Asked the Patients Instead
A 315-person survey found 4 in 10 people who inject drugs in Baltimore have had a xylazine wound. A companion study asked them why — and pointed straight at gaps in clinician training.
Science & MedicineJUUL Is Legal Again — and the FDA's Whole Fix Is a Password Screen
The agency just authorized a new JUUL device built around an optional age-gate app, betting the benefit to adult smokers outweighs the risk to teenagers. Meanwhile the one new medicine that could actually treat nicotine addiction just got turned away — over a factory inspection.
Science & MedicineGetting High With Friends Is the Riskier Choice — If You Already Have a Problem
A September 2026 Addiction study of 104 adults found that using cannabis around other people amplifies craving and continued use, but only for those with more severe cannabis problems.